GlobeNewswire·Aug 14, 2026, 8:00 AM ET

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

Enrollment for the primary analysis of the Phase 2 monotherapy portion of the PYNNACLE clinical trial in platinum-resistant/refractory ovarian cancer patients has been completed.
PMV Pharmaceuticals plans to submit a New Drug Application (NDA) for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
The company reported cash, cash equivalents, & marketable securities of $79.4 million as of June 30, 2026, providing a cash runway through the second quarter of 2027.
Net loss for the quarter ended June 30, 2026, was $18.1 million, a decrease from $21.2 million in the same period in 2025, driven by reduced contract research organization & finance support costs.
Research & development expenses decreased to $14.7 million for the quarter ended June 30, 2026, from $18.4 million in the prior year period.
General & administrative expenses were $4.2 million for the quarter ended June 30, 2026, down from $4.5 million in the prior year period due to lower personnel & finance costs.
Rezatapopt is a first-in-class p53 reactivator with Fast Track & Orphan Drug Designations for specific TP53 Y220C mutant solid tumors.
The PYNNACLE trial is a Phase 1/2 registrational study evaluating rezatapopt at 2000 mg once-daily across approximately 70 sites for advanced solid tumors harboring the TP53 Y220C mutation.